Concepedia

Publication | Open Access

A Phase I Clinical Trial of the hu14.18-IL2 (EMD 273063) as a Treatment for Children with Refractory or Recurrent Neuroblastoma and Melanoma: a Study of the Children's Oncology Group

DOIFull Paper Access

179

Citations

27

References

2006

Year

Kaci L. Osenga, Jacquelyn A. Hank, Mark R. Albertini, Jacek Gan, Adam Sternberg, Jens C. Eickhoff, Robert C. Seeger, Katherine K. Matthay, C. Patrick Reynolds, Clare J. Twist,
Clinical Cancer Research

Abstract

Hu14.18-IL2 (EMD 273063) can be administered safely with reversible toxicities in pediatric patients at doses that induce immune activation. A phase II clinical trial of hu14.18-IL2, administered at a dose of 12 mg/m2/d x 3 days repeated every 28 days, will be done in pediatric patients with recurrent/refractory neuroblastoma.

References

YearCitations

Page 1